In:
Obstetrical & Gynecological Survey, Ovid Technologies (Wolters Kluwer Health), Vol. 77, No. 1 ( 2022-1), p. 30-31
Kurzfassung:
(Abstracted from N Engl J Med 2021;385:1856–1867) Platinum-based chemotherapy plus bevacizumab and paclitaxel is the standard first-line therapy for persistent, recurrent, or metastatic cervical cancer. The phase 2 KEYNOTE-158 trial found evidence of a response to pembrolizumab among patients with programmed death ligand-1 (PD-L1) positive cervical cancer.
Materialart:
Online-Ressource
ISSN:
1533-9866
,
0029-7828
DOI:
10.1097/01.ogx.0000805152.09501.f1
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2022
ZDB Id:
2043471-6
Permalink